TherapeuticsMD (TXMD) Downgraded by ValuEngine

TherapeuticsMD (NASDAQ:TXMD) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Wednesday, ValuEngine reports.

A number of other equities analysts also recently issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 price objective on shares of TherapeuticsMD in a report on Monday, January 21st. BidaskClub upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Tuesday, February 5th. reiterated a “buy” rating and issued a $14.00 price objective on shares of TherapeuticsMD in a report on Tuesday, February 12th. Oppenheimer reiterated a “buy” rating on shares of TherapeuticsMD in a report on Tuesday, March 19th. Finally, Noble Financial reissued an “outperform” rating and issued a $13.00 target price on shares of TherapeuticsMD in a research note on Tuesday, April 30th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. TherapeuticsMD has a consensus rating of “Hold” and an average price target of $12.75.

TXMD traded down $0.06 during trading on Wednesday, reaching $3.25. The stock had a trading volume of 5,490,655 shares, compared to its average volume of 3,031,271. The company has a current ratio of 3.39, a quick ratio of 3.28 and a debt-to-equity ratio of 1.26. The company has a market cap of $796.03 million, a price-to-earnings ratio of -5.51 and a beta of 1.96. TherapeuticsMD has a one year low of $3.19 and a one year high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The business had revenue of $3.95 million during the quarter, compared to the consensus estimate of $5.96 million. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.11) earnings per share. On average, analysts predict that TherapeuticsMD will post -0.64 EPS for the current year.

In other news, Director Jules A. Musing sold 17,400 shares of the stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $5.80, for a total value of $100,920.00. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $29,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 22.85% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc grew its stake in shares of TherapeuticsMD by 9.8% in the third quarter. Vanguard Group Inc now owns 12,894,027 shares of the company’s stock worth $84,585,000 after acquiring an additional 1,153,716 shares during the last quarter. Frontier Capital Management Co. LLC purchased a new stake in shares of TherapeuticsMD during the fourth quarter valued at $5,700,000. Virtu Financial LLC purchased a new stake in shares of TherapeuticsMD during the first quarter valued at $249,000. Teachers Advisors LLC boosted its position in shares of TherapeuticsMD by 13.3% during the third quarter. Teachers Advisors LLC now owns 353,895 shares of the company’s stock valued at $2,322,000 after buying an additional 41,607 shares during the last quarter. Finally, Dfpg Investments Inc. purchased a new stake in shares of TherapeuticsMD during the fourth quarter valued at $38,000. 80.03% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Article: Depreciation

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.